These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12038784)

  • 21. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.
    Björkman S
    Haemophilia; 2011 Mar; 17(2):179-84. PubMed ID: 21299739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B.
    Suzuki A; Tomono Y; Korth-Bradley JM
    Haemophilia; 2016 Sep; 22(5):e359-66. PubMed ID: 27353956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
    Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
    J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of Rixubis™ in the treatment of hemophilia B.
    Valentino LA
    Immunotherapy; 2014; 6(4):381-94. PubMed ID: 24815779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.
    Enjolras N; Perot E; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
    Haemophilia; 2015 Jul; 21(4):e317-21. PubMed ID: 25981983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy.
    Brooks AR; Sim D; Gritzan U; Patel C; Blasko E; Feldman RI; Tang L; Ho E; Zhao XY; Apeler H; Murphy JE
    J Thromb Haemost; 2013 Sep; 11(9):1699-706. PubMed ID: 23692404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Moret A; Caunedo P; Aznar JA; Woodward MK; Páez A
    Haemophilia; 2013 Sep; 19(5):674-8. PubMed ID: 23647607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring.
    Björkman S
    Haemophilia; 2013 Sep; 19(5):753-7. PubMed ID: 23731351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis.
    Björkman S; Shapiro AD; Berntorp E
    Haemophilia; 2001 Mar; 7(2):133-9. PubMed ID: 11260271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX.
    Le Quellec S; Enjolras N; Perot E; Girard J; Negrier C; Dargaud Y
    Thromb Haemost; 2018 Dec; 118(12):2053-2063. PubMed ID: 30453348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of acquired factor IX inhibitors in cynomolgus monkey (Macaca fascicularis): a new primate model of hemophilia B.
    Tomokiyo K; Teshima K; Nakatomi Y; Watanabe T; Mizuguchi J; Nozaki C; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Thromb Res; 2001 May; 102(4):363-74. PubMed ID: 11369429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.
    Windyga J; Abbuehl BE; Hafeman AE
    Expert Rev Hematol; 2014 Jun; 7(3):333-42. PubMed ID: 24832133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
    Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
    J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
    N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
    Collins PW; Quon DVK; Makris M; Chowdary P; Kempton CL; Apte SJ; Ramanan MV; Hay CRM; Drobic B; Hua Y; Babinchak TJ; Gomperts ED
    Haemophilia; 2018 Jan; 24(1):104-112. PubMed ID: 28833808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
    Korth-Bradley JM; Rendo P; Smith L; Altisent C
    Clin Ther; 2016 Apr; 38(4):936-44. PubMed ID: 26969334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GlycoPEGylated recombinant factor IX for hemophilia B in context.
    Santagostino E; Mancuso ME
    Drug Des Devel Ther; 2018; 12():2933-2943. PubMed ID: 30254423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
    Björkman S
    Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    J Med Econ; 2017 Apr; 20(4):337-344. PubMed ID: 27885871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.
    Shapiro AD; Di Paola J; Cohen A; Pasi KJ; Heisel MA; Blanchette VS; Abshire TC; Hoots WK; Lusher JM; Negrier C; Rothschild C; Roth DA
    Blood; 2005 Jan; 105(2):518-25. PubMed ID: 15383463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.